This content is Free Access.
26,634 Views
•
06:15 min
•
October 27, 2014
DOI:
Summary
Automatically generated
A novel methodology that is employed for the treatment of recurrent glioblastomas is described. This treatment approach employs the application of alternating electric tumor treating fields (TTFields), known as TTF Therapy in combination with bevacizumab, a targeted agent that is currently FDA approved as monotherapy.
Read Article
Cite this Article
Omar, A. I. Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma. J. Vis. Exp. (92), e51638, doi:10.3791/51638 (2014).
Copy